Laboratory for Aging Research and Nanotoxicology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University , and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China .
Hum Gene Ther. 2018 Feb;29(2):110-120. doi: 10.1089/hum.2017.226.
With the growing interest in application of nonviral vectors for drug delivery, diagnosis, and imaging, progress has been made in the field of nonviral vector gene therapy in China. Nanobiotechnology studies are important to the development plan for China's research priorities in the 21st century; the National 973 Plan and "Strategic Priority Research Program" classify nanobiotechnology as a special project and give priority to supporting its development. From 2000 to 2017, many articles on nonviral vector gene therapy were published, and cancer gene therapy is one of the most active and important gene therapy research fields. Although the use of nonviral vectors for gene therapy faces enormous problems, Chinese scientists have also begun to realize both the challenges and opportunities that lie ahead. However, a nonviral gene therapy drug has yet to be approved for sale. Therefore, more work is needed in this field. The present review examines the progress and challenges of nonviral gene therapy in China. Efforts to optimize nonviral vectors with structural modifications and gene delivery systems are described, and clinical translation challenges are highlighted.
随着非病毒载体在药物输送、诊断和成像方面应用的兴趣日益浓厚，中国在非病毒载体基因治疗领域取得了进展。纳米生物技术研究对中国 21 世纪研究重点的发展计划很重要；国家 973 计划和“重点战略研究计划”将纳米生物技术列为专项，并优先支持其发展。2000 年至 2017 年，发表了许多关于非病毒载体基因治疗的文章，癌症基因治疗是最活跃和最重要的基因治疗研究领域之一。尽管非病毒载体在基因治疗中的应用面临着巨大的问题，但中国科学家也开始意识到前面的挑战和机遇。然而，一种非病毒基因治疗药物尚未获得销售批准。因此，这一领域还需要更多的工作。本综述考察了中国非病毒基因治疗的进展和挑战。描述了通过结构修饰和基因传递系统优化非病毒载体的努力，并强调了临床转化的挑战。
